Celcuity Inc. (CELC): Price and Financial Metrics
GET POWR RATINGS... FREE!
CELC Stock Price Chart Interactive Chart >
CELC Price/Volume Stats
| Current price | $5.50 | 52-week high | $33.01 |
| Prev. close | $5.66 | 52-week low | $4.81 |
| Day low | $4.81 | Volume | 146,407 |
| Day high | $5.83 | Avg. volume | 51,170 |
| 50-day MA | $7.66 | Dividend yield | N/A |
| 200-day MA | $13.83 | Market Cap | 82.06M |
Celcuity Inc. (CELC) Company Bio
Celcuity LLC, a cellular analysis company, discovers cancer sub-types and commercializes diagnostic tests to enhance the response rates of cancer patients treated with targeted therapies in the United States. It develops CELx tests to diagnose breast, lung, colon, ovarian, kidney, bladder, and hematological cancers. The company was founded in 2012 and is based in Minneapolis, Minnesota.
Latest CELC News From Around the Web
Below are the latest news stories about Celcuity Inc that investors may wish to consider to help them evaluate CELC as an investment opportunity.
FDA Grants Fast Track Tags To Drug Candidates For Antares Pharma, Celcuity, CelularityThe FDA has granted Fast Track designation to Antares Pharma Inc''s (NASDAQ: ATRS ) for ATRS-1902 for adrenal crisis rescue. The development program for ATRS-1902 supports a proposed indication of acute adrenal insufficiency, known as adrenal crisis, in adults and adolescents, using Vai proprietary auto-injector platform to deliver a liquid stable formulation of hydrocortisone. The |
Celcuity Receives FDA Fast Track Designation for Gedatolisib in HR+ / HER2- Metastatic Breast Cancer and Provides Corporate Update* FDA's Fast Track Designation for the pan-PI3K/mTOR inhibitor highlights potential to address the urgent need for new treatment options for breast cancer patients * On track to finalize Phase 3 clinical trial design for gedatolisib with FDA feedback in first quarter * Planning to initiate two studies in breast cancer to evaluate gedatolisib in patients selected with a CELsignia testMINNEAPOLIS, MN / ACCESSWIRE / January 18, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology comp |
Celcuity Inc. (NASDAQ:CELC) Receives $40.40 Average Target Price from AnalystsCelcuity Inc. (NASDAQ:CELC) has earned an average rating of Buy from the seven research firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings [] |
Celcuity (CELC) Gets a Buy Rating from NeedhamIn a report released today, Gil Blum from Needham maintained a Buy rating on Celcuity (CELC – Research Report), with a price target of $50.00. The company's shares closed last Friday at $13.55. According to TipRanks.com, Blum has 0 stars on 0-5 stars ranking scale with an average return of -27.2% and a 8.9% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Crispr Therapeutics AG, and Rocket Pharmaceuticals. Currently, the analyst consensus on Celcuity is a Moderate Buy with an average price target of $50.00. |
Celcuity Inc.: Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Combination with Palbociclib and Endocrine Therapy for ER+ Advanced Breast Cancer (ABC) at the 2021 San Antonio Breast Cancer Symposium78% ORR in 3rd line patients and 63% ORR overall in patients treated with three weeks on/one week off gedatolisib dosing schedule (Arm D)MINNEAPOLIS, MN / ACCESSWIRE / December 10, 2021 / Celcuity |
CELC Price Returns
| 1-mo | N/A |
| 3-mo | -51.11% |
| 6-mo | -65.90% |
| 1-year | -79.35% |
| 3-year | -75.66% |
| 5-year | N/A |
| YTD | -58.30% |
| 2021 | 44.00% |
| 2020 | -13.91% |
| 2019 | -55.65% |
| 2018 | 26.60% |
| 2017 | N/A |
Loading social stream, please wait...